公开(公告)号：WO2011086509A1

公开(公告)日：2011-07-21

申请号：PCT/IB2011/050137

申请日：2011-01-12

申请人： VASCULAR BIOGENICS LTD. ,  BANGIO, Livnat ,  SHER, Naamit ,  BREITBART, Eyal

发明人： BANGIO, Livnat ,  SHER, Naamit ,  BREITBART, Eyal

IPC分类号： A61K39/00 ,  C07K14/475 ,  C12N7/02 ,  C12N15/861

CPC分类号： C12N15/87 ,  C07K2319/00 ,  C12N7/00 ,  C12N2710/10343 ,  C12N2710/10352 ,  C12N2830/008

摘要： The present invention, in some embodiments thereof, relates to methods of producing adenoviruses such as pro- and anti-angiogenic adenovirus vectors and preparations generated thereby. Particularly, in some embodiments, the viral vectors comprise a heterologous pro- or anti-angiogenic gene under the transcriptional control of the murine pre-proendothelin promoter (e.g. PPE-1-3X), for targeted expression of in angiogenic endothelium.

摘要翻译： 本发明在其一些实施方案中涉及产生腺病毒的方法，例如促血管生成腺病毒载体和抗血管生成腺病毒载体以及由此产生的制剂。 特别地，在一些实施方案中，病毒载体在鼠前期内皮素启动子（例如PPE-1-3X）的转录控制下包含用于靶向表达血管生成内皮的异源原或抗血管生成基因。

公开(公告)号：WO2013033642A1

公开(公告)日：2013-03-07

申请号：PCT/US2012/053533

申请日：2012-08-31

申请人： VASCULAR BIOGENICS LTD. ,  SHER, Naamit ,  YOUNG, Victor, M. ,  MCNAUGHTON, Alyn ,  BAKHSHAEE, Massoud ,  WILDING, Ian, Robert

发明人： SHER, Naamit ,  YOUNG, Victor, M. ,  MCNAUGHTON, Alyn ,  BAKHSHAEE, Massoud ,  WILDING, Ian, Robert

IPC分类号： A61K9/48 ,  A61K31/66 ,  A61K47/00 ,  A61P29/00

CPC分类号： A61K31/685 ,  A61K9/4808 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875 ,  A61K9/4891 ,  A61K31/661 ,  Y02A50/411 ,  Y02A50/414

摘要： The current disclosure provides pharmaceutical compositions containing an oxidized phospholipid, such as l-hexadecyl-2-(4'-carboxybutyl)-glycero-3-phosphocholine (VB-201) and a thermosoftening carrier, e.g., a poloxamer. The pharmaceutical compositions may further comprise an anti-adherent agent, such as talc and/or a thixotropic agent. The current disclosure further provides processes for preparing the pharmaceutical compositions. The disclosure further provides capsules containing the pharmaceutical compositions. Uses of such pharmaceutical compositions and capsules in treating inflammatory disorders are also disclosed.

摘要翻译： 本公开提供了含有氧化磷脂的药物组合物，例如1-十六烷基-2-（4'-羧丁基） - 甘油-3-磷酸胆碱（VB-201）和热软化载体，例如泊洛沙姆。 药物组合物还可以包含抗粘连剂，例如滑石和/或触变剂。 本公开进一步提供了制备药物组合物的方法。 本公开进一步提供含有药物组合物的胶囊。 还公开了这些药物组合物和胶囊在治疗炎症性疾病中的用途。

公开(公告)号：WO2011083464A2

公开(公告)日：2011-07-14

申请号：PCT/IL2011/000007

申请日：2011-01-05

申请人： VASCULAR BIOGENICS LTD. ,  COHEN, Yael ,  SHER, Naamit ,  FEIGE, Erez ,  BANGIO, Livnat ,  BREITBART, Eyal

发明人： COHEN, Yael ,  SHER, Naamit ,  FEIGE, Erez ,  BANGIO, Livnat ,  BREITBART, Eyal

IPC分类号： A61K48/00

CPC分类号： C12N15/86 ,  A61K38/177 ,  A61K48/005 ,  A61K48/0058 ,  A61K48/0083 ,  C07K14/70578 ,  C07K14/7151 ,  C07K2319/00 ,  C12N15/87 ,  C12N2799/022 ,  C12N2830/008 ,  C12N2830/85

摘要： Anti-angiogenic adenovirus vectors, and therapeutic use thereof are provided, and more particularly, but not exclusively, clinical protocols for treatment of solid tumors in patients with an Ad5-PPE-1-3X-fas-chimera adenovirus vector.

摘要翻译： 本发明提供了抗血管生成腺病毒载体及其治疗用途，更具体地但非唯一地，用于在Ad5-PPE-1-3X-嵌合体腺病毒载体的患者中治疗实体瘤的临床方案。

公开(公告)号：WO2021199003A1

公开(公告)日：2021-10-07

申请号：PCT/IB2021/052786

申请日：2021-04-02

申请人： VASCULAR BIOGENICS LTD.

发明人： MINEI, Tami Rachmilewitz ,  MENDEL, Itzhak ,  ISHAI, Eti ,  SHER, Naamit ,  FEIGE, Erez ,  BREITBART, Eyal ,  YACOV, Niva

IPC分类号： A61K31/66 ,  A61K31/683 ,  C07C43/10 ,  C07C59/125

摘要： The present invention is directed to methods of treating or preventing inflammation caused by a coronavirus infection with oxidized lipid compounds (e.g., VB-201). The present invention also directed to methods of treating or preventing an infectious disease or symptom caused by a coronavirus infection with oxidized lipid compounds. The present invention is also directed to kits comprising an oxidized lipid and instructions for administering the oxidized lipid to a subject having or suspected of having inflammation or an infectious disease or symptom caused by a coronavirus infection.

公开(公告)号：WO2014118643A2

公开(公告)日：2014-08-07

申请号：PCT/IB2014/000704

申请日：2014-02-04

申请人： VASCULAR BIOGENICS LTD.

发明人： LEUBITZ, Andrea, Rachel ,  SHER, Naamit ,  FEIGE, Erez ,  BREITBART, Eyal

IPC分类号： A61K48/00

CPC分类号： A61K48/0058 ,  A61K38/1793 ,  A61K38/191 ,  A61K39/3955 ,  C07K14/70578 ,  C07K16/22 ,  C12N2710/10343 ,  A61K2300/00

摘要： The invention provides methods of inducing or improving responsiveness to a VEGF antagonist to a subject or a subject population comprising administering an adenovirus comprising a nucleic acid construct comprising a FAS-chimera gene operably linked to an endothelial cell-specific promoter and administering the VEGF antagonist.

摘要翻译： 本发明提供诱导或改善对受试者或受试者群体对VEGF拮抗剂的反应性的方法，包括施用包含与内皮细胞特异性启动子可操作地连接并施用VEGF拮抗剂的FAS嵌合基因的核酸构建体的腺病毒。

公开(公告)号：WO2013121300A2

公开(公告)日：2013-08-22

申请号：PCT/IB2013/000780

申请日：2013-02-15

申请人： VASCULAR BIOGENICS LTD.

发明人： SHER, Naamit ,  LEUBITZ, Andrea ,  BREITBART, Eyal

IPC分类号： A61K31/685

CPC分类号： A61K31/685 ,  A61K9/146 ,  A61K9/4866 ,  A61K45/06 ,  A61K47/02 ,  A61K47/10

摘要： Described are methods of decreasing vascular inflammation in a subject suffering from a chronic autoimmune or chronic inflammatory disease by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Also described are methods of treating inflammation associated with an implant (e.g., a breast implant) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 20 mg/day to about 160 mg/day, optionally administered in two daily sub-doses. Further described are methods of treating psoriasis (e.g., active plaque psoriasis) in a subject by administering to the subject a therapeutically effective amount of VB-201, wherein the therapeutically effective amount is from about 80 mg/day to about 160 mg/day, optionally administered in two daily sub-doses, and wherein the psoriasis prior to the administering the VB-201 is characterized by a body surface area (BSA) from about 20% to about 30 %, or a PASI score that is from about 10 to about 20 (i.e., moderate to severe psoriasis).

摘要翻译： 描述了通过向受试者施用治疗有效量的VB-201来减少患有慢性自身免疫性或慢性炎性疾病的受试者的血管炎症的方法，其中治疗有效量为约20mg /天至约160mg / 天，任选地以两个每日次剂量施用。 还描述了通过向受试者施用治疗有效量的VB-201来治疗与受试者中的植入物（例如，乳房植入物）相关的炎症的方法，其中治疗有效量为约20mg /天至约160 mg /天，任选地以两个每日次剂量施用。 进一步描述的是通过向受试者施用治疗有效量的VB-201治疗受试者的牛皮癣（例如活动性斑块性银屑病）的方法，其中治疗有效量为约80mg /天至约160mg /天， 任选地以两个每日次剂量施用，并且其中在施用VB-201之前的牛皮癣的特征在于体表面积（BSA）为约20％至约30％，或PASI评分为约10至 约20例（即中度至重度银屑病）。

公开(公告)号：WO2011083465A1

公开(公告)日：2011-07-14

申请号：PCT/IL2011/000008

申请日：2011-01-05

申请人： VASCULAR BIOGENICS LTD. ,  COHEN, Yael ,  SHER, Naamit ,  MENDEL, Itzhak ,  YACOV, Niva ,  BREITBART, Eyal

发明人： COHEN, Yael ,  SHER, Naamit ,  MENDEL, Itzhak ,  YACOV, Niva ,  BREITBART, Eyal

IPC分类号： A01N57/00

CPC分类号： A61K31/685 ,  A61K31/198 ,  A61K31/366 ,  A61K31/40 ,  A61K31/505 ,  A61K31/683 ,  A61K38/02 ,  A61K45/06 ,  Y02A50/414

摘要： Unit dosage forms comprising between 1 mg and 100 mg VB-201 and a pharmaceutically acceptable carrier, and formulated for oral administration, are disclosed herein, as well as treatment regimens comprising oral administration of VB-201 once or twice daily for treating an inflammatory disease or disorder.

摘要翻译： 本文公开了包含1mg至100mg的VB-201和药学上可接受的载体并且配制用于口服给药的单位剂量，以及包括每天一次或两次口服VB-201治疗炎性疾病的治疗方案 或障碍。